Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Core Insights - Tevogen Bio is experiencing significant public interest in its investigational precision T cell therapy, TVGN 489, which is being developed for COVID-19 and Long COVID [1][2] - The CEO of Tevogen Bio highlighted the urgent need for effective solutions for Long COVID patients, emphasizing the company's commitment to advancing its research [2] - The clinical trial for TVGN 489 has shown a favorable safety profile and has provided insights for further development, with results published in a peer-reviewed journal [2] Development Plans - Tevogen is preparing for the next stage of development for TVGN 489 and plans to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite the process [3][7] - The company has established a dedicated communication channel for Long COVID updates to manage the high volume of patient inquiries [4][7] Financial Strategy - Tevogen is focused on maximizing capital efficiency and maintaining access to financing to support its growth and commercialization efforts [4]